• Recruitment of second cohort of patients into Phase 2a ACCENT trial in pancreatic cancer underway
• Three additional confirmed partial responses in Phase 2a trial, bringing total to 9
• Research collaboration initiated with Next&Bio to test FAK inhibitors with kRas inhibitors

Amplia Therapeutics Limited (ASX: ATX) announced further progress across its small molecule, focal adhesion kinase (FAK) inhibitor program and the release of its Appendix 4C Cash Flow Report for the quarter ending 31 December 2024. Key highlights include the recruitment of the second and final cohort of patients into the ACCENT Phase 2a trial in pancreatic cancer, with 12 patients of the required 24 recruited by mid-December. The company also reported three additional confirmed partial responses (PRs) from the initial 26 patient cohort of the Phase 2a trial, bringing the total to 9 confirmed PRs. This represents an objective response rate of ~35%, significantly better than the 23% reported for the historical trial being used as the benchmark. The median duration on trial for the 26 patients was 172 days, representing a 47% improvement over the historical data of 117 days. Additionally, the company announced a research collaboration with Next&Bio, a Korean company specializing in drug screening using patient-derived cancer cells, to test the effectiveness of Amplia's FAK inhibitors in killing pancreatic cancer cells when combined with kRas inhibitors. Amplia finished the December 2024 quarter with a strong cash position of $13.7 million, having completed a capital raise of $13.0 million during the quarter.

The company will continue to focus on timely execution of the Phase 2a portion of the ACCENT trial, with a particular focus on completion of enrolment of the remaining 24 patients required. The US trial of narmafotinib, in combination with the chemotherapy regimen FOLFIRINOX, is also being actively progressed in the coming quarters.

Additional clinical opportunities for narmafotinib, including preclinical studies with novel combination therapies, are being actively explored and will be reported as data comes to hand.